Story thread · 2 reports / 2 sources
Lenacapavir PrEP: No New HIV infections & High Satisfaction
medscape.com · 12h · first report
How the coverage leans
Across 2 sources · syndicated copies counted once
Participants in the PURPOSE 1 trial particularly appreciated the convenience of not needing a daily pill and the confidence of feeling protected from HIV long-term. Medscape Medical News
The coverage
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.